TLDR:
- Marea Therapeutics, a biotechnology company based in San Francisco, raised $190M in funding.
- The funding will be used to advance its MAR001 Phase 2 development plan and additional pipeline programs.
Marea Therapeutics, incubated by Third Rock Ventures, secured $190 million in combined Series A and B financings. The Series A round was led by Third Rock Ventures, while the Series B round was led by Sofinnova Investments and co-led by Forbion, Perceptive Xontogeny Venture Fund, and venBio. Additional participants included Alpha Wave Global, Omega Funds, and Citadel company Surveyor Capital. The company, led by CEO Josh Lehrer, M.D., M.Phil., FACC, focuses on developing medicines for cardiometabolic diseases using the latest advances in human genetics. Its lead program, MAR001, is in Phase 2 clinical development to lower remnant cholesterol in adults at high risk for cardiovascular disease. The founding team of Marea Therapeutics includes industry experts like Charles Homcy, M.D., and Sir Stephen O’Rahilly, M.D., FRS. With this funding, Marea Therapeutics aims to advance its clinical development plans and expand its pipeline programs.
